TP53-Mutated Acute Myeloid Leukemia: Unanswered Questions - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40459096/
TP53-mutated acute myeloid leukemia (AML) remains one of the most treatment-resistant hematologic malignancies, with poor overall survival despite advancements in therapeutic strategies. The loss of functional p53 compromises DNA repair,...
TP53-mutated AML is highly treatment-resistant, with poor survival despite chemotherapy, HMAs, venetoclax, and immunotherapies. Current strategies show limited efficacy, highlighting the urgent need for multi-targeted combination approaches and precision medicine.
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39936576/
The availability of 12 newly approved agents has been welcomed; however, optimal strategies incorporating newer agents into therapeutic algorithms are debated. The overarching approach integrates patient and caregiver goals of...
Acute myeloid leukemia management has evolved with advanced diagnostics, molecular risk classification, measurable residual disease monitoring, and integration of 12 new therapies, emphasizing individualized, risk-adapted approaches aligned with patient goals and comorbidities.